Lithium-carbamazepine neurotoxicity and risk factors



	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map



	Email this article to a Colleague
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Articles & Searches
	Download to citation manager



	Citing Articles via HighWire
	Citing Articles via Google Scholar



	Articles by Shukla, S.
	Articles by Miller, M. G.
	Search for Related Content



	PubMed Citation
	Articles by Shukla, S.
	Articles by Miller, M. G.

Am J Psychiatry 1984; 141:1604-1606
Copyright © 1984 by American Psychiatric Association

REGULAR ARTICLES

Lithium-carbamazepine neurotoxicity and risk factors

S Shukla, CD Godwin, LE Long and MG Miller

Five rapid-cycling manic patients developed neurotoxic syndromes when treated with a combination of lithium and carbamazepine, although all five had therapeutic plasma levels of both drugs. The risk factors for development of neurotoxicity with this drug combination are discussed.

This article has been cited by other articles:

M. W. Linder and P. E. Keck Jr.
Standards of laboratory practice: antidepressant drug monitoring
Clin. Chem., May 1, 1998; 44(5): 1073 - 1084.
[Abstract] [Full Text] [PDF]

M. P. Freeman and A. L. Stoll
Mood Stabilizer Combinations: A Review of Safety and Efficacy
Am J Psychiatry, January 1, 1998; 155(1): 12 - 21.
[Abstract] [Full Text]

M. J. Brodie and M. A. Dichter
Antiepileptic Drugs
N. Engl. J. Med., January 18, 1996; 334(3): 168 - 175.
[Full Text] [PDF]

L. H. Price and G. R. Heninger
Lithium in the Treatment of Mood Disorders
N. Engl. J. Med., September 1, 1994; 331(9): 591 - 598.
[Full Text]

M. Elphick, F. Lyons, and P.J. Cowen
Low tolerability of carbamazepine in psychiatric patients may restrict its clinical usefulness
J Psychopharmacol, January 1, 1988; 2(1): 1 - 4.
[Abstract] [PDF]

Get information about faster international access.